Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
MICA NCT05302037 MICA receptor ligand recognition CTM-N2D C167220 CAR T Cellular Therapy Allogeneic, mRNA-electroporated NKG2D-based CAR-grafted gamma-delta T-cell therapy targeting NKG2D ligands (MICA/B, ULBP1-6) on stressed tumor cells; retains native γδ TCR and DNAM-1 signaling. Allogeneic gamma-delta T cells engineered by mRNA electroporation to transiently express an NKG2D-based CAR that binds NKG2D ligands (MICA/MICB, ULBP1-6) on stressed tumor and tumor microenvironment cells; engagement activates CAR and native gamma-delta TCR/DNAM-1 signaling to drive pro-inflammatory cytokine release and MHC-independent cytotoxic killing. Engineered gamma-delta T cells expressing an NKG2D-based CAR bind MICA on target cells, activating MHC-independent cytotoxicity via perforin/granzyme-mediated lysis. Relapsed Cancer CANCER Other Solid Tumors Other Cancer ai
MICB NCT05302037 MICB receptor ligand recognition CTM-N2D C167220 CAR T Cellular Therapy Allogeneic, mRNA-electroporated NKG2D-based CAR-grafted gamma-delta T-cell therapy targeting NKG2D ligands (MICA/B, ULBP1-6) on stressed tumor cells; retains native γδ TCR and DNAM-1 signaling. Allogeneic gamma-delta T cells engineered by mRNA electroporation to transiently express an NKG2D-based CAR that binds NKG2D ligands (MICA/MICB, ULBP1-6) on stressed tumor and tumor microenvironment cells; engagement activates CAR and native gamma-delta TCR/DNAM-1 signaling to drive pro-inflammatory cytokine release and MHC-independent cytotoxic killing. NKG2D-based CAR γδ T cells bind MICB on target cells, activating CAR and native γδ TCR/DNAM-1 signaling to induce MHC-independent cytolysis via perforin/granzyme release and pro-inflammatory cytokines. Relapsed Cancer CANCER Other Solid Tumors Other Cancer ai
ULBP1 NCT05302037 ULBP1 receptor ligand recognition CTM-N2D C167220 CAR T Cellular Therapy Allogeneic, mRNA-electroporated NKG2D-based CAR-grafted gamma-delta T-cell therapy targeting NKG2D ligands (MICA/B, ULBP1-6) on stressed tumor cells; retains native γδ TCR and DNAM-1 signaling. Allogeneic gamma-delta T cells engineered by mRNA electroporation to transiently express an NKG2D-based CAR that binds NKG2D ligands (MICA/MICB, ULBP1-6) on stressed tumor and tumor microenvironment cells; engagement activates CAR and native gamma-delta TCR/DNAM-1 signaling to drive pro-inflammatory cytokine release and MHC-independent cytotoxic killing. NKG2D-based CAR on allogeneic gamma-delta T cells binds ULBP1 on target cells, triggering CAR/TCR signaling and degranulation (perforin/granzyme) to kill the bound cells in an MHC-independent manner. Relapsed Cancer CANCER Other Solid Tumors Other Cancer ai
ULBP2 NCT05302037 ULBP2 receptor ligand recognition CTM-N2D C167220 CAR T Cellular Therapy Allogeneic, mRNA-electroporated NKG2D-based CAR-grafted gamma-delta T-cell therapy targeting NKG2D ligands (MICA/B, ULBP1-6) on stressed tumor cells; retains native γδ TCR and DNAM-1 signaling. Allogeneic gamma-delta T cells engineered by mRNA electroporation to transiently express an NKG2D-based CAR that binds NKG2D ligands (MICA/MICB, ULBP1-6) on stressed tumor and tumor microenvironment cells; engagement activates CAR and native gamma-delta TCR/DNAM-1 signaling to drive pro-inflammatory cytokine release and MHC-independent cytotoxic killing. NKG2D-CAR–engineered gamma-delta T cells bind ULBP2 on target cells, triggering T-cell activation and MHC-independent cytolysis via perforin/granzyme release (and related cytotoxic pathways). Relapsed Cancer CANCER Other Solid Tumors Other Cancer ai
ULBP3 NCT05302037 ULBP3 receptor ligand recognition CTM-N2D C167220 CAR T Cellular Therapy Allogeneic, mRNA-electroporated NKG2D-based CAR-grafted gamma-delta T-cell therapy targeting NKG2D ligands (MICA/B, ULBP1-6) on stressed tumor cells; retains native γδ TCR and DNAM-1 signaling. Allogeneic gamma-delta T cells engineered by mRNA electroporation to transiently express an NKG2D-based CAR that binds NKG2D ligands (MICA/MICB, ULBP1-6) on stressed tumor and tumor microenvironment cells; engagement activates CAR and native gamma-delta TCR/DNAM-1 signaling to drive pro-inflammatory cytokine release and MHC-independent cytotoxic killing. NKG2D-CAR on engineered γδ T cells binds ULBP3 on target cells, activating CAR/γδ T-cell signaling to mediate MHC-independent killing via perforin/granzyme and pro-inflammatory cytokines. Relapsed Cancer CANCER Other Solid Tumors Other Cancer ai
Displaying 1571 - 1575 of 3741